Background: Responses to inhaled corticosteroids (ICSs) and leukotriene receptor antagonists (LTRAs) vary among asthmatic patients.
Objective: We sought to determine whether responses to ICSs and LTRAs are concordant for individuals or whether asthmatic patients who do not respond to one medication respond to the other.
Methods: Children 6 to 17 years of age with mild-to-moderate persistent asthma were randomized to one of 2 crossover sequences, including 8 weeks of an ICS, fluticasone propionate (100 microg twice daily), and 8 weeks of an LTRA, montelukast (5-10 mg nightly depending on age), in a multicenter, double-masked, 18-week trial. Response was assessed on the basis of improvement in FEV 1 and assessed for relationships to baseline asthma phenotype-associated biomarkers.
Results: Defining response as improvement in FEV 1 of 7.5% or greater, 17% of 126 participants responded to both medications, 23% responded to fluticasone alone, 5% responded to montelukast alone, and 55% responded to neither medication. Compared with those who responded to neither medication, favorable response to fluticasone alone was associated with higher levels of exhaled nitric oxide, total eosinophil counts, levels of serum IgE, and levels of serum eosinophil cationic protein and lower levels of methacholine PC(20) and pulmonary function; favorable response to montelukast alone was associated with younger age and shorter disease duration. Greater differential response to fluticasone over montelukast was associated with higher bronchodilator use, bronchodilator response, exhaled nitric oxide levels, and eosinophil cationic protein levels and lower methacholine PC(20) and pulmonary function values.
Conclusions: Response to fluticasone and montelukast vary considerably. Children with low pulmonary function or high levels of markers associated with allergic inflammation should receive ICS therapy. Other children could receive either ICSs or LTRAs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaci.2004.11.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Restitutio ad integrum: Rescuing the Alveolar Macrophage Function with HSCT in Pulmonary Alveolar Proteinosis Due to CSF2Rα Deficiency.
J Clin Immunol
December 2024
Department of Blood and Marrow Transplantation, Bai Jerbai Wadia Hospital for Children, Mumbai, India, 400012.
Hereditary pulmonary alveolar proteinosis (hPAP) is a rare lung-related primary immunodeficiency. In hPAP, variants of genes encoding the heterodimeric GM-CSF receptor alpha or beta-chains (CSF2Rα, CSF2Rβ) lead to perturbations in GM-CSF signalling. These perturbations impair the scavenging function of pulmonary alveolar macrophages leading to accumulation of surfactant proteins and lipids within the alveoli.
View Article and Find Full Text PDFPost-Stevens-Johnson Syndrome Bronchiolitis Obliterans: Report of a Complex Case and a Literature Review.
Cureus
November 2024
Respiratory Medicine, Dartford and Gravesham National Health Service (NHS) Trust, Dartford, GBR.
Bronchiolitis obliterans (BO) is a rare and severe respiratory complication of Stevens-Johnson syndrome (SJS), which primarily affects the small airways and causes progressive respiratory decline. We present the case of a young male with autism spectrum disorder who developed BO after an episode of SJS triggered by amoxicillin. Initially, the patient presented with an ulcerative rash and respiratory symptoms and received high-dose corticosteroids, leading to partial resolution of mucocutaneous lesions.
View Article and Find Full Text PDFPharmacologic Treatment of Eosinophilic Esophagitis: Efficacious, Likely Efficacious, and Failed Drugs.
Inflamm Intest Dis
July 2024
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Article Synopsis
- Eosinophilic esophagitis (EoE) is a chronic condition driven by food allergies that causes changes in the esophagus, necessitating treatment options like medications, dietary changes, and dilation.
- Recently approved treatments include oral budesonide tablets (Jorveza) in Europe, Canada, and Australia, and an orodispersible budesonide suspension (Eohilia) in the USA, both shown to effectively induce and maintain remission in EoE patients.
- Other treatment considerations include off-label proton-pump inhibitors, which have inconsistent results, and Dupilumab, a monoclonal antibody approved for EoE treatment in multiple regions, available for older adolescents and adults who don't respond to
Introduction: Allergic rhinitis (AR) is increasingly prevalent in India, affecting a significant portion of the population and adversely impacting their quality of life. This nationwide survey aimed to explore the perceptions and clinical preferences of Indian physicians regarding the perceived prevalence, common symptoms, and various available treatments for AR.
Methods: This cross-sectional, observational, digital questionnaire-based survey was conducted from September 2022 to March 2023, involving physicians sharing insights on prevalence rates, diagnostic approaches, medication preferences, and immunotherapy practices in AR management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!